Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arvinas, Inc. (NASDAQ: ARVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on targeted protein degradation. Arvinas files current reports on Form 8-K, along with periodic reports such as Forms 10-K and 10-Q, to describe material events, financial results and key developments across its PROTAC pipeline.
In its 8-K filings, Arvinas reports items such as quarterly financial results and corporate updates, presentation of clinical and preclinical data for programs including ARV-102 (a PROTAC LRRK2 degrader), ARV-393 (a BCL6 degrader for non-Hodgkin lymphoma) and ARV-806 (a KRAS G12D degrader for solid tumors), and regulatory milestones for vepdegestrant, its investigational PROTAC estrogen receptor degrader for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. The company also uses 8-Ks to disclose collaboration updates with Pfizer, workforce and cost management actions, and Board and executive changes.
Through this page, users can review how Arvinas describes its PROTAC platform, clinical-stage programs and corporate actions in official SEC documents. Real-time updates from EDGAR allow investors to see new 8-Ks and other filings as they are posted, while AI-powered tools on Stock Titan can help summarize lengthy filings, highlight key sections on topics such as clinical data, regulatory status and capital allocation, and surface patterns across multiple ARVN disclosures.
For those researching ARVN, these filings are a primary source for understanding the status of vepdegestrant’s New Drug Application, the design and progress of trials in oncology and neurodegeneration, and the financial and governance information Arvinas reports to regulators and shareholders.
ARVINAS, INC. President and CEO Randy Teel reported an automatic sale of 4,403 shares of common stock on February 13, 2026 at $11.89 per share. According to the filing, the issuer executed this sale solely to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on February 13, 2026, and it was not a discretionary trade. Following this transaction, Teel beneficially owned 154,482 shares of Arvinas common stock directly.
Arvinas, Inc.’s Chief Financial Officer Andrew Saik reported an automatic share sale related to tax withholding. On February 13, 2026, 5,134 shares of common stock were sold at $11.89 per share to cover tax obligations triggered by the vesting and settlement of 25% of his restricted stock units granted on February 13, 2025. The filing notes this was not a discretionary trade. After this transaction, Saik’s directly held stake is 159,267 shares of Arvinas common stock.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic sale of common stock tied to tax withholding. On February 13, 2026, 4,592 shares of common stock were sold in an open-market transaction at $11.89 per share to cover tax obligations from RSU vesting. After this transaction, Cacace directly owned 151,232 common shares, which include 1,576 shares previously acquired under the company’s 2018 Employee Stock Purchase Plan. The filing notes the sale did not represent a discretionary trade.
Arvinas, Inc. Chief Medical Officer Noah Berkowitz reported an automatic sale of 5,685 shares of common stock at $11.89 per share. The shares were sold by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on February 13, 2025. The transaction was not a discretionary trade. After this sale, Berkowitz directly holds 163,938 shares of Arvinas common stock.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock to cover taxes tied to restricted stock units. On February 13, he sold 1,016 shares of common stock at an average price of $11.89 per share in an open-market transaction.
The footnotes explain this sale was made by the company to satisfy tax withholding obligations upon vesting and settlement of 25% of RSUs granted on February 13, 2025, and that it was not a discretionary trade. After this sale, Loomis directly owns 30,800 shares, including 119 shares previously purchased under the company’s 2018 Employee Stock Purchase Plan.
Arvinas, Inc. President and CEO Randy Teel reports his direct holdings of common stock and stock options in the company. The filing lists multiple option and restricted stock unit grants made between 2018 and 2025, with vesting schedules extending through 2029 and generally contingent on continued service. It also notes shares previously purchased under the 2018 Employee Stock Purchase Plan. The report does not show any stock purchases or sales, only existing equity awards and holdings.
Arvinas, Inc. shareholder plans a modest Rule 144 stock sale. A holder has filed to sell 5,685 shares of Arvinas common stock through Morgan Stanley Smith Barney LLC on or around 02/13/2026 on the NASDAQ.
The filing lists an aggregate market value of 67,605.35 for the shares to be sold, compared with 64,224,294 Arvinas common shares outstanding. The shares were acquired on 02/13/2026 through settlement of vested restricted stock units from Arvinas, Inc.
A shareholder of Arvinas, Inc. has filed a notice to sell 4,592 common shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 54607.52. The issuer had 64224294 shares outstanding, and the approximate sale date is 02/13/2026.
The securities were acquired on 02/13/2026 through settlement of vested restricted stock units from Arvinas, Inc., with payment also dated 02/13/2026 and described as not applicable, indicating no separate cash purchase at that time.
Arvinas, Inc. insider plans small stock sale under Rule 144. A person for whose account the shares are held filed to sell 4,403 shares of Arvinas common stock through Morgan Stanley Smith Barney LLC on or about 02/13/2026 on the NASDAQ market, with an aggregate market value of $52,359.96. These shares were acquired the same day through settlement of vested restricted stock units granted by Arvinas, Inc. The filing notes that shares outstanding were 64,224,294, providing context for the sale’s relative size.
Arvinas, Inc. had an affiliated holder file a Form 144 notice to sell 5,134 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 02/13/2026 on the NASDAQ market. The shares have an aggregate market value of $61,052.92 based on the figures provided.
The securities to be sold arose from the settlement of vested restricted stock units acquired from Arvinas on 02/13/2026, with payment noted as not applicable. Common shares outstanding were 64,224,294 at the time referenced, providing context for the relative size of this planned sale.